What are the final symptomies for Hepatisis C?

Question

I'm in final stages of Hepatisis C and Liver Cirrohes what final symptoms can I expect?

Answer 1

Check out http://www.cdc.gov/ncidod/diseases/hepatitis/c/ for more info on Hepatitis C. I feel sorry to hear that.

Answer 2

Final stages? I would think that the symptom is death. My mothers best friend had both...went through hell for several years and her final symptom was death..pretty permanent and severe but the truth. It just gets worse and worse till it kills you. She bloated up with fluids, was fatigued, didn't think right because of lack of blood flow to the brain due to the cirrhosis. She basically wasn't herself the last year or so and just passed in June. Sorry to hear you are suffering from them both...God Bless.

Answer 3

usually the kidney's are affected to the point where the overload of toxins affect other organs. your skin will seep body fluids as it has no other way to escape, there is no sense in dialysis. the heart will be affected and eventually give out. usually a person will end up in a coma state and will not know they are dying.

i am sorry you are going through this, i have a chance of liver cancer due to hcv-even though my hcv status is now 0 because of antiviral chemotherapy. i also suffer with NASH which further increases my chance of cirrhosis even though the hcv is gone.

prayers are with you.

Answer 4

I am very sorry to hear this.....go to www.webmd.com and put hepatitis c and search. You will find many answers there that might make you understand which other symptoms to expect, Iam not equipped to give those answers. Good luck and God bless you.

Answer 5

Hi,
A very effective method I use to cure my neuropathy problems can be found here http://www.goobypls.com/r/rd.asp?gid=569

This program really helped me a lot
Cheers.

Answer 6

Not good my friend, not good.
Hasn't your doctor spoken to you about this?
www.hepnet.com
that'll give you some answers without me going into any details.

good luck, hope you arent drinking (no offense)..might be a little late for milk thistle but hey, you never know.

Answer 7

I have hep c e-mail me at [e-mail]

Answer 8

your Dr. should be the one to discuss this with you if he hasn't already

Answer 9

liver and kidney failure

Answer 10

Hepatitis C: The Clinical Spectrum of Disease

Jay H. Hoofnagle, M.D.

The hepatitis C virus (HCV) is an important cause of both acute and chronic hepatitis. As with all diseases, the clinical course and outcome of hepatitis C are variable - there is no single natural history of disease, but rather a broad clinical spectrum of disease presentations and outcomes.

In the United States, hepatitis C represents approximately 20 percent of cases of acute hepatitis. The mean incubation period to onset of symptoms is 7 weeks; the range is 3-20 weeks. However, long before onset of symptoms, markers of virus appear in the serum: HCV RNA is detectable within 1-3 weeks of exposure and rises rapidly to levels of 106-108 genomes per ml. After several weeks, serum alanine aminotransferase levels (ALT) begin to rise and shortly thereafter clinical symptoms appear. The severity of the acute illness is variable; virtually all infected patients have a transient elevation in ALT with peak levels greater than tenfold elevated. Yet only a third of patients develop jaundice or symptoms: in the remainder, the disease is anicteric and subclinical. If clinically apparent, the illness generally lasts 2-12 weeks. Acute hepatitis C can result in fulminant hepatitis, but this is quite rare. In cases of acute, self-limited disease, HCV RNA becomes undetectable within a few weeks of onset of symptoms and aminotransferase levels return to normal.

Unfortunately, the majority of patients with acute hepatitis C develop chronic infection; symptoms of acute hepatitis resolve, but ALT levels remain elevated and HCV RNA persists. Indeed, a propensity to chronicity is the most distinguishing characteristic of HCV infection, occurring in at least 85 percent of patients with acute HCV infection. The factors that lead to chronicity in hepatitis C are not well defined. The quasispecies nature of HCV and the tendency of the envelope gene of the virus to mutate rapidly may be key factors, the virus constantly escaping immune recognition by mutations in the antigenic epitopes to which any neutralizing antibody is made. The role of cellular immunity to HCV antigens in explaining why 15 percent of patients clear HCV infection while the majority do not may also be important.

Not all patients who continue to be viremic continue to have raised ALT levels. In most surveys, approximately one-third of patients with chronic HCV infection have persistently normal serum ALT levels, and in others ALT levels are only intermittently abnormal. These patients have been referred to as "healthy HCV carriers," but this term is misleading and should be avoided. Liver biopsies in patients with chronic HCV infection with normal ALT levels reveal histological evidence of chronic hepatitis in virtually all patients. Perhaps more appropriate is to say that these patients have mild or subclinical chronic hepatitis C: their prognosis may be excellent.

The majority of patients with chronic HCV infection have raised ALT levels, which can fluctuate widely over time. There is not a very good correlation between the height of the ALT levels and disease severity as judged histologically. Long-term followup studies, however, suggest that most patients with progressive liver disease who develop cirrhosis have prominent ALT elevations; these can, however, be intermittent.

A smaller proportion of patients with chronic HCV infection have clinical symptoms or signs of liver disease. Symptoms in chronic hepatitis C tend to be nonspecific, mild, and intermittent. The most frequent symptom is fatigue, variably described as lethargy, malaise, lack of energy or stamina, and easy fatigability. Often, it is a challenge to determine whether the fatigue is attributable to the liver disease rather than to something else - depression, anxiety over the illness, aging, sleep disturbance, or another medical condition. Other, less frequent symptoms are nausea, poor appetite, muscle aches, arthralgias, feverishness, weakness, and weigh loss. Symptoms are rarely incapacitating, but they can cause a decrease in the quality of life. In general, patients with higher ALT levels and more severe disease histologically are more likely to have symptoms, but marked exceptions exist. Because the symptoms are nonspecific, it is hard to define what percentage of patients with chronic HCV infection are symptomatic; but it is probably less than 20 percent. These are the patients, however, who are most likely to present to a physician for diagnosis and management.

Chronic hepatitis C, whether or not symptoms are present, can lead to cirrhosis and end-stage liver disease. Cirrhosis can develop rapidly, within 1-2 years of exposure, or slowly, within 2-3 decades. In studies with 10-20 years of followup, cirrhosis develops in 20-30 percent of patients. It is unclear whether the remaining patients will eventually develop cirrhosis or not. Thus, chronic hepatitis C probably does not have one typical course; there are probably multiple typical courses, from rapidly progressive to slowly progressive to nonprogressive.

Once cirrhosis develops, the symptoms of end-stage liver disease can appear, such as marked fatigue, muscle weakness and wasting, fluid retention, easy bruisability, upper intestinal hemorrhage, jaundice, dark urine, and itching. Nevertheless, some patients with cirrhosis remain asymptomatic of liver disease until they have major complications of cirrhosis, such as variceal hemorrhage or ascites or they die of an unrelated cause. Hepatitis C ranks with alcoholic liver disease as the most common cause of cirrhosis and the major indication for liver transplantation in the United States. Liver transplantation is the only means of restoring health to patients with end-stage liver disease due to HCV. Recurrent infection of the new graft occurs in almost all patients, but in many cases the recurrent infection is mild. Long-term studies are needed to assess at what rate recurrent hepatitis C leads to recurrence of cirrhosis. At present, long-term survival after liver transplantation for hepatitis C is similar to that for other diagnoses, averaging 65 percent after 5 years.

In many areas of the world, chronic hepatitis C is a major cause of hepatocellular carcinoma (HCC). This tumour occurs largely in patients with long-standing disease, and the majority have cirrhosis. Therapies for HCC are unsatisfactory and focus must be on prevention of development of cirrhosis and early detection of liver cancer.

The spectrum of hepatitis C also includes several nonhepatic manifestations, including arthritis, keratoconjunctivitis sicca, lichen planus, glomerulonephritis, and essential mixed cryoglobulinemia (EMC). EMC is a syndrome marked by varying combinations of fatigue, muscle and joint aches, arthritis, skin rash (hives, purpura, or vasculitis), neuropathy, and glomerulonephritis. Cryoglobulins are found in serum composed of immune complexes of HCV and anti-HCV, immunoglobulins, rheumatoid factor, and complement. Hepatitis C appears to be the most common cause of EMC, a fact that was not appreciated before the availability of serological tests for HCV. Cryoglobulins are detectable in up to one-third of patients with chronic hepatitis C, but the clinical syndrome of EMC occurs in only 1-2 percent of patients. This syndrome can be severe, incapacitating, and even fatal. Resolution of the hepatitis C is followed by resolution of the EMC. Glomerulonephritis can also occur with hepatitis C; it usually represents the renal involvement of HCV-related EMC. Overall, this syndrome might best be called HCV-related systemic vasculitis.

A final clinical manifestation of chronic hepatitis C is porphyria cutanea tarda (PCT). This form of porphyria is found in several forms of chronic liver disease often in association with iron overload. In some parts of the world, hepatitis C is the major underlying cause of PCT. Like other forms, HCV-related PCT can be treated with phlebotomy to deplete the excess iron stores that exacerbate the porphyria.

Thus, there is a wide clinical spectrum to acute and chronic hepatitis C. Simple and reliable systems to stage and grade the severity of chronic hepatitis C are needed. Histological systems such as the histology activity index (HAI) have been developed to categorize chronic hepatitis C for use in clinical studies of natural history and therapy. A possible system which mixes clinical symptoms, serum biochemical tests, and liver histology would be as follows:

Disease activity: Mild (ALT normal or <2 times upper limit)
Moderate (ALT 2-5 times upper limit)
Severe (ALT >5 times upper limit)
Cirrhosis: Present or absent
Symptoms: Present or absent

Bibliography

1. Houghton M, Weiner A, Han J, et al. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991;14:381-8.

2. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23:437-55.

3. Alter JH, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-500.

4. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98-104.

5. Alter HJ, Sanchez-Pescador R, Urdea MS, et al. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepatitis 1995;2:121-32.

6. Weiner AJ, Geysen HM, Christopherson C, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992;89:3468-72.

7. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic and histologic features. Ann Intern Med 1995;123:330-7.

8. Alberti A, Morsica G, Chemello L, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340:697-8.

9. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-11.

10. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.

11. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.

12. Detre KM, Belle SH. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Reviews. In press.

13. Colombo M, Kuo G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-9.

14. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70.

15. Agnello V, Chung RT, Kaplan LM. A role of hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-5.

16. DeCastro M, Sanchez J, Herrera JF, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17:551-7.

17. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
Biotech Firms Report Advances in Hepatitis C Drugs

By Justin Gillis
Washington Post Staff Writer
Tuesday, January 10, 2006; Page D04

Shares of two biotechnology companies jumped yesterday after they reported some of the best results ever seen in treatment of a serious liver virus, the latest indication that a cure for hepatitis C could be at hand in a few years -- just in time to rescue millions of baby boomers with the ailment.

Shares of Idenix Pharmaceuticals Inc. of Cambridge, Mass., jumped 18 percent after the company reported study results for its hepatitis C treatment that were strong enough to surprise many investors. Shares of Vertex Pharmaceuticals Inc., also of Cambridge, rose a more modest 6 percent after the company reported striking results in one of its studies. Many investors had been expecting strong data from Vertex based on prior studies, and they have bid the company's stock up 216 percent in the past year.

Who's Blogging?
Read what bloggers are saying about this article.

* Post-Genomics


Full List of Blogs (1 links) »

Most Blogged About Articles
On washingtonpost.com | On the web

Vertex, developing what many experts perceive to be the most potent of the new hepatitis medicines, said yesterday that when the pill was combined in a small, early-stage study with an existing treatment, the drug cut the amount of hepatitis C virus in patients' bodies to a minuscule fraction of its prior level in just two weeks of treatment. In past studies, dramatic drops in the amount of virus have been a prelude to cures in many patients, but it has often taken months if it happened at all.

"No one's ever seen anything like this," said Joshua S. Boger, chief executive of Vertex. Donald M. Jensen, a University of Chicago liver doctor and board member of the American Liver Foundation, called the data "truly exciting."

Many Americans think of hepatitis as a serious but short-term ailment they get from eating tainted food in foreign countries. That's hepatitis A. Hepatitis B and C are slower but far nastier, damaging people's livers over the course of decades until they lead to life-threatening problems such as cancer and liver failure. At least 2.7 million Americans -- nearly 1 percent of the population -- are chronically infected with hepatitis C, making it the largest blood-borne infection in the country and a looming health crisis as many of those people progress toward serious disease.

Using two anti-viral medicines that were not specifically designed to attack hepatitis C, doctors reached the point several years ago where they could eliminate the virus in roughly half of patients. But the treatment is arduous, requiring up to a year of pills and injections that can cause flu-like symptoms and other side effects. More importantly, the treatment does not work for a majority of people who have the most common strain of hepatitis C virus.

Speaking this week at an investor conference in California, several companies are laying out research plans that they believe will transform the field of hepatitis treatment over the next several years. At least a half-dozen companies appear to be closing in on new, potent treatments that were specifically designed to attack the hepatitis C virus.

"Just over a year ago, the hepatitis C area was one of frustration and negative news," said Colin Broom, chief scientific officer of ViroPharma Inc. of Exton, Pa., which is working on one promising treatment. "Since then, the whole area has been transformed."

ViroPharma reported no new data for its drug yesterday, but the company's shares still jumped 11 percent, apparently driven higher by investor focus on the whole category of hepatitis treatments.

The furthest-along of the new treatments is one under development by Schering-Plough Corp. of Kenilworth, N.J., which had been a leader in earlier treatments for hepatitis C. The big company -- whose shares rose 1 percent yesterday -- has launched advanced human studies of its drug, though the product may still be several years from final approval by the Food and Drug Administration.

Most of the other drugs are in early human tests, and it is far too soon to predict which might win approval. Drugs often fail in large, late-stage tests because of side effects. That happened several years ago with a hepatitis C treatment that looked promising. But liver experts believe at least some of the new drugs will win approval eventually, giving doctors treatment combinations that will cure hepatitis C in a large majority of patients.

"I think you're seeing a major advance in this field," said Eugene R. Schiff, director of the Center for Liver Diseases at the University of Miami and one of the country's leading experts on hepatitis. "Things are moving rapidly, and I would certainly encourage anyone with hepatitis C to get evaluated."

Companies are modeling their research on the previous success that drug companies had in treating AIDS. Once companies developed multiple drugs that could target the human immunodeficiency virus at different steps in its reproductive cycle, doctors achieved dramatic success in restoring patients' health. In hepatitis C, company scientists are exploiting some of the same drug-design strategies that worked against HIV.

The biggest difference is that HIV infection is permanent, and most people must take drug treatment for life to combat it. But a growing body of evidence suggests that hepatitis C can be eradicated from the body.

"This is a cure that we're working on," Broom said.